Roth Capital Starts Sophiris Bio (SPHS) at Buy, $8 PT
Tweet Send to a Friend
Roth Capital initiates coverage on Sophiris Bio (NASDAQ: SPHS) with a Buy rating and a price target of $8.00.Analyst Joseph ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE